OPN -443C>T genetic polymorphism and tumor OPN expression are associated with the risk and clinical features of papillary thyroid cancer in a Chinese cohort

Cellular Physiology and Biochemistry

Volumn 32, Issue 1, 2013, Pages 171-179

  Mu, Guoyu ^a   Wang, Hongjiang ^a   Cai, Zhengang ^a   Ji, Hong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Osteopontin; Papillary thyroid cancer; Polymorphism; Risk

Indexed keywords

OSTEOPONTIN;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER SURGERY; CHINESE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PAPILLARY THYROID CANCER; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID CANCER;

ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CHINA; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; ODDS RATIO; OSTEOPONTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; THYROID NEOPLASMS;

EID: 84880183260     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350133     Document Type: Article

References (45)

1. Al-Zahrani AS, Ravichandran K: Epidemiology of thyroid cancer: a review with special reference to Gulf Cooperation Council (GCC) states. Gulf J Oncolog 2007;2:17-28.
2. Colonna M, Bossard N, Guizard AV, Remontet L, Grosclaude P: Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival. Ann Endocrinol (Paris) 2010;71:95-101.
3. Nagataki S, Nystrom E: Epidemiology and primary prevention of thyroid cancer. Thyroid 2002;12:889-896.
4. Akslen L: Thyroid-cancer-some aspects of epidemiology and etiologic factors, pathological features and tumor biology. Int J Oncol 1994;4:931-942.
5. Sipos JA, Mazzaferri EL: Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010;22:395-404.
6. Miccoli P, Miccoli M, Antonelli A, Minuto MN: Clinicopathologic and molecular disease prognostication for papillary thyroid cancer. Expert Rev Anticancer Ther 2009;9:1261-1275.
7. Agate L, Lorusso L, Elisei R: New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest 2012;35:3-9.
8. Fincham SM, Ugnat AM, Hill GB, Kreiger N, Mao Y: Is occupation a risk factor for thyroid cancer? Canadian Cancer Registries Epidemiology Research Group. J Occup Environ Med 2000;42:318-322.
9. Kitahara CM, Neta G, Pfeiffer RM, Kwon D, Xu L, Freedman ND, Hutchinson AA, Chanock SJ, Sturgis EM, Sigurdson AJ, Brenner AV: Common obesity-related genetic variants and papillary thyroid cancer risk. Cancer Epidemiol Biomarkers Prev 2012;21:2268-2271.
10. Hucz J, Kowalska M, Jarzab M, Wiench M: Gene expression of metalloproteinase 11, claudin 1 and selected adhesion related genes in papillary thyroid cancer. Endokrynol Pol 2006;57:S18-25.
11. Aschebrook-Kilfoy B, Neta G, Brenner AV, Hutchinson A, Pfeiffer RM, Sturgis EM, Xu L, Wheeler W, Doody MM, Chanock SJ, Sigurdson AJ: Common genetic variants in metabolism and detoxification pathways and the risk of papillary thyroid cancer. Endocr Relat Cancer 2012;19:333-344.
12. Romei C, Fugazzola L, Puxeddu E, Frasca F, Viola D, Muzza M, Moretti S, Nicolosi ML, Giani C, Cirello V, Avenia N, Rossi S, Vitti P, Pinchera A, Elisei R: Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab 2012;97:E1758-1765.
13. Giachelli CM, Steitz S: Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000;19:615-622.
14. Heilmann K, Hoffmann U, Witte E, Loddenkemper C, Sina C, Schreiber S, Hayford C, Holzlöhner P, Wolk K, Tchatchou E, Moos V, Zeitz M, Sabat R, Günthert U, Wittig BM: Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med 2009;13:1162-1174.
15. Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB: Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009;76:32-43.
16. Zhivkova-Galunska M, Adwan H, Eyol E, Kleeff J, Kolb A, Bergmann F, Berger MR: Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biol Ther 2010;10:54-64.
17. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF: Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008;122:889-897.
18. Wu Y, Jiang W, Wang Y, Wu J, Saiyin H, Qiao X, Mei X, Guo B, Fang X, Zhang L, Lou H, Wu C, Qiao S: Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS One 2012;7:e42976.
19. Beausoleil MS, Schulze EB, Goodale D, Postenka CO, Allan AL: Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer 2011;11:25.
20. Wu GL, Zhang L, Li TY, Chen J, Yu GY, Li JP: Short-term effect of combined therapy with Jinlong Capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression. Chin J Integr Med 2010;16:109-113.
21. Imano M, Satou T, Itoh T, Sakai K, Ishimaru E, Yasuda A, Peng YF, Shinkai M, Akai F, Yasuda T, Imamoto H, Okuno K, Ito H, Shiozaki H, Ohyanagi H: Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg 2009;13:1577-1582.
22. Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico E, Kruhoffer M, Orntoft TF, Curcio F, Fusco A, Melillo RM, Santoro M: Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene 2004;23:2188-2196.
23. Briese J, Cheng S, Ezzat S, Liu W, Winer D, Wagener C, Bamberger AM, Asa SL: Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Res 2010;30:1681-1688.
24. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M: Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 2005;90:5270-5278.
25. Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, Kao SY: The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol 2010;46:302-306.
26. Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G: Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer 2012;12:477.
27. Xu Q, Yuan B, Xue F, Zhang L, Li J, Guo H, Yue T: OPN gene polymorphisms are associated with susceptibility and clinicopatholigical characteristics of cervical cancer in a Chinese cohort. Cancer Biomark 2011;10:233-239.
28. Dong QZ, Zhang XF, Zhao Y, Jia HL, Zhou HJ, Dai C, Sun HJ, Qin Y, Zhang WD, Ren N, Ye QH, Qin LX: Osteopontin promoter polymorphisms at locus-443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology 2013;57:1024-1034.
29. Soini Y, Kahlos K, Puhakka A, Lakari E, Säily M, Pääkkö P, Kinnula V: Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. Br J Cancer 2000;83:880-886.
30. Cho H, Hong SW, Oh YJ, Kim MA, Kang ES, Lee JM, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 2008;134:909-917.
31. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K, Mack PC: Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 2009;4:1104-1110.
32. Li Y, Li L, Wang JT, Kan X, Lu JG: Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol 2012;29:1429-1434.
33. Sieghart W, Wang X, Schmid K, Pinter M, König F, Bodingbauer M, Wrba F, Rasoul-Rockenschaub S, Peck-Radosavljevic M: Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol 2011;54:89-97.
34. Ding L, Zheng S: [Expression and clinical significance of osteopontin in colorectal cancer and liver metastatic tissues]. Zhonghua Wai Ke Za Zhi 2002;40:773-775.
35. Ding L, Zheng S, Cao J: [Expression of osteopontin mRNA and its protein in colorectal cancer and liver metastatic tissues]. Zhonghua Yi Xue Za Zhi 2002;82:970-973.
36. Ke HL, Chang LL, Yang SF, Lin HH, Li CC, Wu DC, Wu WJ: Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urol Oncol 2011;29:703-709.
37. Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, Shimono M: Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 2007;36:30-34.
38. Shimada Y, Watanabe G, Kawamura J, Soma T, Okabe M, Ito T, Inoue H, Kondo M, Mori Y, Tanaka E, Imamura M: Clinical significance of osteopontin in esophageal squamous cell carcinoma: comparison with common tumor markers. Oncology 2005;68:285-292.
39. Cho H, Kang ES, Kim YT, Kim JH: Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest 2009;27:313-323.
40. Hashiguchi Y, Tsuda H, Bandera CA, Nishimura S, Inoue T, Kawamura N, Berkowitz RS, Mok SC: Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol 2006;23:205-212.
41. Antonelli A, Ferrari SM, Fallahi P, Piaggi S, Di Domenicantonio A, Galleri D, Santarpia L, Basolo F, Ferrannini E, Miccoli P: Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine 2012;59:218-222.
42. Zhao XQ, Dong JH, Zhang WZ, Liu Z: Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin. Diagn Pathol 2011;6:98.
43. Zhang R, Pan X, Huang Z, Weber GF, Zhang G: Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines. PLoS One 2011;6:e23831.
44. Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, Ravazzolo R: Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004;20:87-96.
45. Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M: The functional-443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog 2009;48:14-23.